Text Size

Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: Experience through the French early-access program

Pisella P.-J., Labetoulle M., Doan S., Cochener-Lamard B., Amrane M., Ismail D., Creuzot-Garcher C., Baudouin C.


  • 2018
  • Clinical Ophthalmology
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Department of Ophthalmology, Tours University Hospital, University François Rabelais, Bretonneau Hospital, Tours, France; Department of Ophthalmology, Bicêtre Hospital, APHP, Paris-Sud University, Le Kremlin-Bicêtre, France; Department of Ophthalmology, Bichat Hospital, Fondation A de Rothschild, Paris, France; Brest University Medical School, Morvan Hospital, Brest, France; Santen SAS, Evry, France; Department of Ophthalmology, University Hospital, France; Department of Ophthalmology III, Eye and Nutrition Research Group, Burgundy, Dijon, France; Research Team S12, Quinze-Vingts National Ophthalmology Hospital, France; Department of Ophthalmology, Ambroise-Paré Hospital, APHP, UPMC University, Paris 6, Vision Institute, INSERM UMRS968, CNRS UMR7210, Paris, France; University of Versailles Saint-Quentin en Yvelines, Versailles, France

Related Publications

Burden of Vernal Keratoconjunctivitis in the United States: A Retrospective Claims Database Analysis

Koo E.B.; Yu T.M.; Layton A.J.; Babineaux S.; Fung S.


Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.


Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis

Ogura N., Fujisawa K., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022